Safety and efficacy of combined tixagevimab and cilgavimab administered intramuscularly or intravenously in nonhospitalized patients with COVID-19: 2 randomized …
RAB Ignacio, KW Chew, C Moser, JS Currier… - JAMA Network …, 2023 - jamanetwork.com
Importance Development of effective, scalable therapeutics for SARS-CoV-2 is a priority.
Objective To test the efficacy of combined tixagevimab and cilgavimab monoclonal …
Objective To test the efficacy of combined tixagevimab and cilgavimab monoclonal …
Casirivimab/imdevimab: first approval
ED Deeks - Drugs, 2021 - Springer
Abstract Casirivimab/imdevimab (Ronapreve™; REGEN-COV™) is a co-packaged
combination of two neutralizing immunoglobulin gamma 1 (IgG1) human monoclonal …
combination of two neutralizing immunoglobulin gamma 1 (IgG1) human monoclonal …
Casirivimab and imdevimab treatment in seropositive, hospitalized COVID-19 Patients with non-neutralizing or borderline neutralizing antibodies
AT Hooper, S Somersan-Karakaya, SE McCarthy… - medRxiv, 2022 - medrxiv.org
We conducted a post-hoc analysis in seropositive patients who were negative or borderline
for functional neutralizing antibodies (nAbs) against SARS-CoV-2 at baseline from a phase …
for functional neutralizing antibodies (nAbs) against SARS-CoV-2 at baseline from a phase …
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open …
Background Dysregulated inflammation is associated with poor outcomes in COVID-19. We
aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating …
aimed to assess the efficacy of namilumab (a granulocyte-macrophage colony stimulating …
Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: A single-center, propensity-matched cohort study
C Rhudy, S Bochenek, J Thomas… - American Journal of …, 2023 - academic.oup.com
Purpose To evaluate the success of a clinic for subcutaneous administration of casirivmab
and imdevimab (REGEN-COV; Regeneron) for treatment of patients with symptomatic mild …
and imdevimab (REGEN-COV; Regeneron) for treatment of patients with symptomatic mild …
Casirivimab and imdevimab treatment reduces viral load and improves clinical outcomes in seropositive hospitalized COVID-19 patients with nonneutralizing or …
AT Hooper, S Somersan-Karakaya, SE McCarthy… - Mbio, 2022 - Am Soc Microbiol
We conducted a post hoc analysis in seropositive patients who were negative or borderline
for functional neutralizing antibodies (NAbs) against severe acute respiratory syndrome …
for functional neutralizing antibodies (NAbs) against severe acute respiratory syndrome …
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled …
M Hites, CR Massonnaud, EL Lapique… - Journal of …, 2024 - journalofinfection.com
We read with great interest the recent article by Kamboj et al., in which they described the
risk of developing moderate to severe Coronavirus Disease 2019 (COVID-19) in patients …
risk of developing moderate to severe Coronavirus Disease 2019 (COVID-19) in patients …
A living WHO guideline on drugs for covid-19
R RECOMMENDATIONS - bmj, 2020 - bmj.com
New recommendations (1) A conditional recommendation to use a combination of
casirivimab and imdevimab in nonsevere patients for those at highest risk of severe …
casirivimab and imdevimab in nonsevere patients for those at highest risk of severe …
A study of outcome in COVID-19 patients receiving casirivimab-imdevimab
P Kulkarni, KN Chintale, M Bhattacharya… - Indian Journal of …, 2023 - ijpp.com
Objectives: In December 2019, coronavirus disease 2019 (COVID-19) was first identified in
Wuhan, China, as a respiratory tract infection causing symptoms, such as fever, chills, dry …
Wuhan, China, as a respiratory tract infection causing symptoms, such as fever, chills, dry …
[HTML][HTML] Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients
SK Hegazy, S Tharwat, AH Hassan - World Journal of Clinical …, 2023 - ncbi.nlm.nih.gov
BACKGROUND Coronavirus disease 2019 (COVID-19) pandemic stimulates research
works to find a solution to this crisis from starting 2020 year up to now. With ending of the …
works to find a solution to this crisis from starting 2020 year up to now. With ending of the …